NASDAQ$CCRN
Cross Country Healthcare Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Announced fourth quarter and full year 2023 financial results.
Cross Country Healthcare's Q4 2023 revenue was $414.0 million, a decrease of 34% year-over-year. Net income attributable to common stockholders was $9.0 million, and diluted EPS was $0.26. The company proactively managed its cost structure, repaid $73.9 million on the term loan, and invested over $20 million in core technologies.
- Fourth quarter Revenue exceeded the high end of guidance range
- Physician Staffing and Education experienced annual double-digit year-over-year revenue growth
- Proactively managed cost structure and drove a full year adjusted EBITDA margin of over 7%
- Repaid $73.9 million on the term loan and paid down the ABL, ending the year debt-free
Headline financials
Revenue & EPS history
Cross Country Healthcare · Revenue · Quarterly
$414M
Revenue by segment
Cross Country Healthcare · $442M total across 2 segments · Q3 2023
- Nurse and Allied Staffing$397M-35.2%89.7%
- Physician Staffing$45.7M+91.8%10.3%
Forward guidance
The company expects Q1 2024 revenue to be between $370 million and $380 million, with adjusted EBITDA between $13.0 million and $18.0 million, and adjusted EPS between $0.15 and $0.25.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-2.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
+0.5%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+24.6%
Q3 2021
Best reaction
-33.6%
Q2 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | +0.4% | +0.8% | |
| Q4 2025 | +8.2% | +7.9% | +0.5% | |
| Q3 2025 | -14.1% | -7.2% | -32.9% | |
| Q1 2025 | +0.4% | +0.8% | -6.7% | |
| Q4 2024 | +0.3% | -6.0% | -13.9% | |
| Q3 2024 | +7.2% | -6.1% | +57.9% | |
| Q2 2024 | -2.7% | -8.2% | -17.3% | |
| Q1 2024 | -4.9% | -9.0% | -14.1% | |
| Q4 2023 | -2.7% | -0.3% | +5.7% | |
| Q3 2023 | -14.0% | -19.0% | -10.7% | |
| Q2 2023 | -14.7% | -14.0% | -3.8% | |
| Q1 2023 | +5.1% | +9.9% | +26.1% | |
| Q4 2022 | -5.6% | +3.2% | -13.2% | |
| Q3 2022 | -2.5% | -11.3% | -2.8% | |
| Q2 2022 | -13.7% | -14.1% | -7.6% | |
| Q1 2022 | -2.6% | -7.1% | +0.9% | |
| Q4 2021 | -1.5% | +6.6% | +2.4% | |
| Q3 2021 | +24.6% | +18.0% | +21.1% | |
| Q2 2021 | +23.0% | +14.6% | +29.7% | |
| Q1 2021 | +16.5% | +24.0% | +17.4% | |
| Q4 2020 | +18.9% | +24.6% | +33.8% | |
| Q3 2020 | -5.0% | -3.0% | +9.3% | |
| Q2 2020 | +9.6% | +4.7% | +1.6% | |
| Q1 2020 | -4.8% | -2.0% | +7.6% | |
| Q4 2019 | +0.4% | -12.2% | -27.7% | |
| Q3 2019 | +14.2% | +16.9% | +10.9% | |
| Q2 2019 | -0.8% | -5.5% | +5.6% | |
| Q1 2019 | +4.7% | +18.7% | +0.9% | |
| Q4 2018 | -3.6% | -11.6% | -22.5% | |
| Q3 2018 | +7.8% | +3.4% | +2.7% | |
| Q2 2018 | -30.9% | -26.0% | -14.7% | |
| Q1 2018 | -16.7% | -11.0% | -4.3% | |
| Q4 2017 | -18.8% | -13.6% | -15.8% | |
| Q3 2017 | -9.6% | -13.8% | -2.6% | |
| Q2 2017 | +3.1% | +1.2% | +2.5% | |
| Q1 2017 | -13.0% | -15.1% | -16.7% | |
| Q4 2016 | +3.4% | -5.3% | -7.2% | |
| Q3 2016 | +22.9% | +24.3% | +31.7% | |
| Q2 2016 | -11.5% | -17.0% | -14.2% | |
| Q1 2016 | +10.0% | — | — | |
| Q4 2015 | -21.9% | — | — | |
| Q3 2015 | +9.5% | — | — | |
| Q2 2015 | +10.1% | — | — | |
| Q1 2015 | -4.6% | — | — | |
| Q4 2014 | -9.6% | — | — | |
| Q3 2014 | -0.5% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | -14.3% | — | — | |
| Q4 2013 | -22.3% | — | — | |
| Q3 2013 | +3.1% | — | — | |
| Q2 2013 | -3.3% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2009 | -5.5% | — | — | |
| Q3 2012 | -0.9% | — | — | |
| Q2 2012 | -5.5% | — | — | |
| Q1 2011 | -3.1% | — | — | |
| Q1 2012 | +11.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q3 2011 | +2.5% | — | — | |
| Q2 2011 | -33.6% | — | — | |
| Q4 2010 | -33.6% | — | — | |
| Q2 2010 | -33.6% | — | — | |
| Q1 2010 | -7.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro